Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Tau13 Antibody Preferentially Immunoprecipitates High Molecular Weight Tau Proteins.

Umstead A, Vega IE.

J Alzheimers Dis. 2019;68(2):511-516. doi: 10.3233/JAD-181187.

2.

Tau's Three-Repeat Domain and EFhd2 Co-incubation Leads to Increased Thioflavin Signal.

Vega IE, Sutter A, Parks L, Umstead A, Ivanova MI.

Front Neurosci. 2018 Dec 3;12:879. doi: 10.3389/fnins.2018.00879. eCollection 2018.

3.

A functional proteomics platform to reveal the sequence determinants of lysine methyltransferase substrate selectivity.

Cornett EM, Dickson BM, Krajewski K, Spellmon N, Umstead A, Vaughan RM, Shaw KM, Versluis PP, Cowles MW, Brunzelle J, Yang Z, Vega IE, Sun ZW, Rothbart SB.

Sci Adv. 2018 Nov 28;4(11):eaav2623. doi: 10.1126/sciadv.aav2623. eCollection 2018 Nov.

4.

EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity.

Peled M, Dragovich MA, Adam K, Strazza M, Tocheva AS, Vega IE, Mor A.

J Immunol. 2018 Nov 1;201(9):2824-2831. doi: 10.4049/jimmunol.1800839. Epub 2018 Oct 1.

PMID:
30275048
5.

Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease.

Vega IE, Umstead A, Wygant CM, Beck JS, Counts SE.

Curr Alzheimer Res. 2018;15(12):1086-1095. doi: 10.2174/1567205015666180813152043.

6.

A START-domain-containing protein is a novel marker of nervous system components of the sea cucumber Holothuria glaberrima.

Rosado-Olivieri EA, Ramos-Ortiz GA, Hernández-Pasos J, Díaz-Balzac CA, Vázquez-Rosa E, Valentín-Tirado G, Vega IE, García-Arrarás JE.

Comp Biochem Physiol B Biochem Mol Biol. 2017 Dec;214:57-65. doi: 10.1016/j.cbpb.2017.08.004. Epub 2017 Aug 31.

7.

Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health.

Vega IE, Cabrera LY, Wygant CM, Velez-Ortiz D, Counts SE.

J Alzheimers Dis. 2017;58(4):979-992. doi: 10.3233/JAD-161261. Review.

8.

Oxidative stress in neurodegenerative disease: causation or association?

Van Raamsdonk JM, Vega IE, Brundin P.

Oncotarget. 2017 Feb 14;8(7):10777-10778. doi: 10.18632/oncotarget.14650. No abstract available.

9.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.

10.

Editorial: Unraveling Neuroprotective and Neurodegenerative Signals in Neurodegeneration.

Vega IE, Collier TJ.

Front Neurosci. 2016 Jul 13;10:328. doi: 10.3389/fnins.2016.00328. eCollection 2016. No abstract available.

11.

Diversity is Inclusion.

Vega IE, Colón-Berlingeri M.

J Undergrad Neurosci Educ. 2016 Apr 15;14(2):E20-1. eCollection 2016 Spring. No abstract available.

12.

Labeling Pathological Tau: An Important Quest for the Unknown.

Vega IE.

Front Neurosci. 2016 Jun 6;10:253. doi: 10.3389/fnins.2016.00253. eCollection 2016. No abstract available.

13.

EFhd2, a Protein Linked to Alzheimer's Disease and Other Neurological Disorders.

Vega IE.

Front Neurosci. 2016 Mar 31;10:150. doi: 10.3389/fnins.2016.00150. eCollection 2016. Review.

14.

Profiling of Alzheimer's disease patients in Puerto Rico: A comparison of two distinct socioeconomic areas.

Camacho-Mercado CL, Figueroa R, Acosta H, Arnold SE, Vega IE.

SAGE Open Med. 2016 Jan 29;4:2050312115627826. doi: 10.1177/2050312115627826. eCollection 2016.

15.

Tanycytic ependymoma in a 76-year-old Puerto Rican male.

Ortiz Ydel M, Pérez Berenguer JL, Mercado Acosta J, Polo M, de Jesús-Garces O, Vega IE.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):7789-94. eCollection 2014.

16.

Cdk5 phosphorylation of EFhd2 at S74 affects its calcium binding activity.

Vázquez-Rosa E, Rodríguez-Cruz EN, Serrano S, Rodríguez-Laureano L, Vega IE.

Protein Sci. 2014 Sep;23(9):1197-207. doi: 10.1002/pro.2499. Epub 2014 Jun 18.

17.

Novel autoimmune response in a tauopathy mouse model.

Nogueras-Ortiz CJ, De Jesús-Cortes HJ, Vaquer-Alicea J, Vega IE.

Front Neurosci. 2014 Jan 10;7:277. doi: 10.3389/fnins.2013.00277. eCollection 2014 Jan 10.

18.

Identification and functional analysis of novel phosphorylation sites in the RNA surveillance protein Upf1.

Lasalde C, Rivera AV, León AJ, González-Feliciano JA, Estrella LA, Rodríguez-Cruz EN, Correa ME, Cajigas IJ, Bracho DP, Vega IE, Wilkinson MF, González CI.

Nucleic Acids Res. 2014 Feb;42(3):1916-29. doi: 10.1093/nar/gkt1049. Epub 2013 Nov 5.

19.

Solution structure of the tandem acyl carrier protein domains from a polyunsaturated fatty acid synthase reveals beads-on-a-string configuration.

Trujillo U, Vázquez-Rosa E, Oyola-Robles D, Stagg LJ, Vassallo DA, Vega IE, Arold ST, Baerga-Ortiz A.

PLoS One. 2013;8(2):e57859. doi: 10.1371/journal.pone.0057859. Epub 2013 Feb 28.

20.

EFhd2 is a novel amyloid protein associated with pathological tau in Alzheimer's disease.

Ferrer-Acosta Y, Rodríguez-Cruz EN, Orange F, De Jesús-Cortés H, Madera B, Vaquer-Alicea J, Ballester J, Guinel MJ, Bloom GS, Vega IE.

J Neurochem. 2013 Jun;125(6):921-31. doi: 10.1111/jnc.12155. Epub 2013 Feb 14.

21.

Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia.

Arnold SE, Vega IE, Karlawish JH, Wolk DA, Nunez J, Negron M, Xie SX, Wang LS, Dubroff JG, McCarty-Wood E, Trojanowski JQ, Van Deerlin V.

J Alzheimers Dis. 2013;33(4):1089-95. doi: 10.3233/JAD-2012-121570.

22.

Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration.

De Jesús-Cortés HJ, Nogueras-Ortiz CJ, Gearing M, Arnold SE, Vega IE.

Neuroreport. 2012 Nov 14;23(16):942-6. doi: 10.1097/WNR.0b013e32835982ce.

23.

Functional and structural analysis of the conserved EFhd2 protein.

Ferrer-Acosta Y, Rodríguez Cruz EN, Vaquer Adel C, Vega IE.

Protein Pept Lett. 2013 May;20(5):573-83.

24.

Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center.

Livney MG, Clark CM, Karlawish JH, Cartmell S, Negrón M, Nuñez J, Xie SX, Entenza-Cabrera F, Vega IE, Arnold SE.

Am J Geriatr Psychiatry. 2011 May;19(5):430-9. doi: 10.1097/JGP.0b013e3181f7d881.

25.

Allylation of intraerythrocytic hemoglobin by raw garlic extracts.

Bonaventura J, Rodriguez EN, Beyley V, Vega IE.

J Med Food. 2010 Aug;13(4):943-9. doi: 10.1089/jmf.2009.0258.

26.

Barnacle cement: a polymerization model based on evolutionary concepts.

Dickinson GH, Vega IE, Wahl KJ, Orihuela B, Beyley V, Rodriguez EN, Everett RK, Bonaventura J, Rittschof D.

J Exp Biol. 2009 Nov;212(Pt 21):3499-510. doi: 10.1242/jeb.029884.

27.

Geographical differences in the occurrence of Alzheimer's disease mortality: United States versus Puerto Rico.

Figueroa R, Steenland K, MacNeil JR, Levey AI, Vega IE.

Am J Alzheimers Dis Other Demen. 2008 Oct-Nov;23(5):462-9. doi: 10.1177/1533317508321909.

28.

A novel calcium-binding protein is associated with tau proteins in tauopathy.

Vega IE, Traverso EE, Ferrer-Acosta Y, Matos E, Colon M, Gonzalez J, Dickson D, Hutton M, Lewis J, Yen SH.

J Neurochem. 2008 Jul;106(1):96-106. doi: 10.1111/j.1471-4159.2008.05339.x. Epub 2008 Jul 1.

29.

Taxol and tau overexpression induced calpain-dependent degradation of the microtubule-destabilizing protein SCG10.

Vega IE, Hamano T, Propost JA, Grenningloh G, Yen SH.

Exp Neurol. 2006 Nov;202(1):152-60. Epub 2006 Jul 5.

30.
31.

Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.

Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH.

Brain Res Mol Brain Res. 2005 Aug 18;138(2):135-44.

32.

Recent advances in experimental modeling of the assembly of tau filaments.

Ko LW, DeTure M, Sahara N, Chihab R, Vega IE, Yen SH.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):125-39. Review.

33.

Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.

Sahara N, Vega IE, Ishizawa T, Lewis J, McGowan E, Hutton M, Dickson D, Yen SH.

J Neurochem. 2004 Aug;90(4):829-38.

35.

Supplemental Content

Support Center